HOOKIPA, an Austrian-based company developing a new class of immunotherapeutics targeting infectious diseases and cancers appointed Instinctif to increase business visibility and support growth.
HOOKIPA needed to attract new investors to fund the development of its programmes originating from its proprietary VaxWave® and TheraT® technologies. It also needed support positioning it for an initial public offering (IPO) on the US NASDAQ stock exchange.
One key challenge was clearly communicating HOOKIPA’s complex scientific story to investors. Another was evolving its messaging to become more US-centric to reflect HOOKIPA’s new US operations.
Instincif provided communications advice and support for HOOKIPA in a number of areas leading up to its IPO on NASDAQ. These included the announcement of a new Leadership team and Board members, the publication of key data relating to its development programmes and collaborations.
Instinctif provided strategic PR counsel and media targeting advice around each announcement.
In addition, Instinctif provided specific advice around the IPO, including communicating the name change from HOOKIPA Biotech to HOOKIPA Pharma and corporate structure, as well as messaging and copy input to the website content.
In April 2019 HOOKIPA raised $37.4 million in a series D financing and then completed an IPO on NASDAQ, raising $84 million in gross proceeds.
Instinctif achieved significant media coverage of HOOKIPA’s news leading up to its series D financing and its IPO on NASDAQ.
Accurate and timely coverage was achieved in leading biotech trade media: Scrip, BioCentury, BioWorld, Fierce Biotech, Labiotech, Endpoints, Vantage, Mednous, Transkript, Pharma Leaders and the European Biotechnology Review. Much of this was achieved following interviews with members of HOOKIPA’s leadership team.
Instinctif continues to provide strategic communications advice to HOOKIPA Pharma as a NASDAQ listed transatlantic public company.